INTRAVITREAL AND INTRACAMERAL BEVACIZUMAB IN NEOVASCULAR GLAUCOMA: AN INTERVENTIONAL CASE SERIES

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KASIRI A.; FEGHHI M.; BORNA F.; CHERAGHIAN B.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2010 | Volume:15 | Issue:4 (61) Page(s): 278-283

Download Full-Text

Persian Verion

View:

870

Download:

Cites:

Information Journal Paper

Title

INTRAVITREAL AND INTRACAMERAL BEVACIZUMAB IN NEOVASCULAR GLAUCOMA: AN INTERVENTIONAL CASE SERIES

Author(s)

KASIRI A. | FEGHHI M. | BORNA F. | CHERAGHIAN B. | Issue Writer Certificate

Keywords

BEVACIZUMABQ3

INTRAVITREAL INJECTIONQ3

INTRACAMERAL INJECTIONQ3

NEOVASCULAR GLAUCOMAQ3

Abstract

Purpose: To evaluate the effects of intravitreal and INTRACAMERAL INJECTION of BEVACIZUMAB in patients with NEOVASCULAR GLAUCOMA (NVG).Methods: This interventional case series was conducted on 40 eyes of 40 patients with NEOVASCULAR GLAUCOMA. Data included the extent of iris (NVI) and angle neovascularization (NVA), peripheral anterior synechia (PAS), and intraocular pressure (IOP). Following standard NVG treatment, 1.5 and 1 mg of BEVACIZUMAB were injected intravitreally and intracamerally, respectively. Six weeks after injection, the same procedure was repeated.Results: Intraocular pressure decreased significantly from 40.15±18.33 to 29.27±15.07 mmHg (P<0.001). NVI and NVA were eliminated in 97.5% and 100% of patients, respectively. No significant change was seen in best corrected visual acuity (BCVA). After the injection, hyphema occurred only in one eye.Conclusion: Intravitreal and INTRACAMERAL INJECTION of BEVACIZUMAB is an effective complementary treatment for reducing NVI and NVA and hence IOP in NVG.

Cites

No record.

References

No record.

Cite

APA: Copy

KASIRI, A., FEGHHI, M., BORNA, F., & CHERAGHIAN, B.. (2010). INTRAVITREAL AND INTRACAMERAL BEVACIZUMAB IN NEOVASCULAR GLAUCOMA: AN INTERVENTIONAL CASE SERIES. BINA, 15(4 (61)), 278-283. SID. https://sid.ir/paper/42829/en

Vancouver: Copy

KASIRI A., FEGHHI M., BORNA F., CHERAGHIAN B.. INTRAVITREAL AND INTRACAMERAL BEVACIZUMAB IN NEOVASCULAR GLAUCOMA: AN INTERVENTIONAL CASE SERIES. BINA[Internet]. 2010;15(4 (61)):278-283. Available from: https://sid.ir/paper/42829/en

IEEE: Copy

A. KASIRI, M. FEGHHI, F. BORNA, and B. CHERAGHIAN, “INTRAVITREAL AND INTRACAMERAL BEVACIZUMAB IN NEOVASCULAR GLAUCOMA: AN INTERVENTIONAL CASE SERIES,” BINA, vol. 15, no. 4 (61), pp. 278–283, 2010, [Online]. Available: https://sid.ir/paper/42829/en

Related Journal Papers